Skip to main content
padlock icon - secure page this page is secure

The Use of Bevacizumab and Trastuzumab Beyond Tumor Progression: A New Avenue in Cancer Treatment?

Buy Article:

$68.00 + tax (Refund Policy)

The use of the Monoclonal Antibodies (MoAbs) Bevacizumab (B) and Trastuzumab (T) beyond clinical progression in colorectal and breast cancer treatment is among the hottest topics in today's clinical oncology. Both observational and prospective studies, based on a sound preclinical basis, seem to support the notion that, simply replacing the cytotoxic drugs combined with the two MoAbs would provide an additional clinical benefit without stopping the biological agent. The aim of this review is to provide a critical analysis of the available clinical data, while waiting for the confirmatory prospective clinical trials still ongoing.

The strength and the weakness of this innovative strategy, as well as the associated expense and toxicity issues will be discussed.

No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Trastuzumab; bevacizumab; breast cancer; colon cancer; use beyond progression

Document Type: Research Article

Publication date: September 1, 2009

More about this publication?
  • Reviews on Recent Clinical Trials publishes frontier reviews on recent clinical trials of major importance. The journal's aim is to publish the highest quality review articles in the field. Topics covered include: important Phase I - IV clinical trial studies, clinical investigations at all stages of development and therapeutics.

    The journal is essential reading for all researchers and clinicians involved in drug therapy and clinical trials.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more